Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All andrographis studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAndrographisAndrographis (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Viral clearance 19% Improvement Relative Risk Time to viral- 31% no CI Andrographis  Prempree et al.  LATE TREATMENT Is late treatment with andrographis beneficial for COVID-19? Retrospective 60 patients in Thailand Study compares with favipiravir, results vs. placebo may differ No significant difference in viral clearance c19early.org Prempree et al., OSIR, December 2022 Favors andrographis Favors favipiravir

SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study

Prempree et al., OSIR, 15:4
Dec 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 120 patients in Thailand, showing improved viral clearance with andrographis compared with favipiravir.
risk of no viral clearance, 18.8% lower, RR 0.81, p = 0.61, treatment 13 of 30 (43.3%), control 16 of 30 (53.3%), NNT 10, day 14.
time to viral-, 30.8% lower, relative time 0.69, treatment 30, control 30, andrographis vs. favipiravir.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Prempree et al., 31 Dec 2022, retrospective, Thailand, peer-reviewed, 9 authors, this trial compares with another treatment - results may be better when compared to placebo.
This PaperAndrographisAll
SARS-CoV-2 Clearance from Andrographis paniculata, Boesenbergia rotunda, and Favipiravir among Mild COVID-19 Cases in Klong Prem Central Prison during Mid-2021: a Retrospective Study
Preecha Prempree, Anek Mungaomklang, Mayuree Tangkiatkumjai, Tuangrat Phodha, Pakakrong Kwankhao, Kanokwan Chewchuapun, Chutima Charuenporn, Darika Monta, Thanawut Karapakdee
This study aims to assess the effectiveness of two herbal medicines, Andrographis paniculata (Burm.f.) Nees capsule (AP) and Boesenbergia rotunda (Linn.) Mansf. extract capsule (BR), on the rate of SARS-CoV-2 virus clearance among inmates of Klong Prem Central Prison, Bangkok. Cases with mild COVID-19 were allocated into four groups: four capsules of AP thrice daily (n=30), one capsule of BR once daily (n=30), a combination of AP and BR (AP-BR) (n=30), or favipiravir (n=30) for five days. The primary outcome was time until undetected SARS-CoV-2 infection after starting treatment. The median period of SARS-CoV-2 clearance was shorter in the AP and AP-BR groups (9 days) compared to the BR (11 days) and favipiravir (13 days) groups. No one developed pneumonia; however, one participant in the AP group developed hyperkalemia. Our results suggest that A. paniculata with or without B. rotunda may be used as an alternative treatment for mild COVID-19 when access to favipiravir is limited. Further clinical trials are needed to determine their efficacy and safety.
Authors' Contributions PP guided and revised the manuscript. AM and PK revised the manuscript. MT analyzed study data and wrote the first draft of the manuscript. TP analyzed study data. KC, CC, DM, and TK carried out the research. All authors approved the final manuscript.
References
Bethesda, Md), ClinicalTrials.gov; 2021 [cited
Hu, Wu, Logue, Blondel, Lai et al., Andrographis paniculata (Chuān Xīn Lián) for symptomatic relief of acute respiratory tract infections in adults and children: a systematic review and meta-analysis
Joshi, Parkar, Ansari, Vora, Talwar et al., Role of favipiravir in the treatment of COVID-19, Int J Infect Dis, doi:10.1016/j.ijid.2020.10.069
Kanjanasirirat, Suksatu, Manopwisedjaroen, Munyoo, Tuchinda et al., High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep, doi:10.1038/s41598-020-77003-3
Numthavaj, Andrographis paniculata vs Boesenbergia rotunda vs control in asymptomatic COVID-19
Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand, Antibiotics (Basel), doi:10.3390/antibiotics11060805
Sa-Ngiamsuntorn, Suksatu, Pewkliang, Thongsri, Kanjanasirirat et al., Anti-SARS-CoV-2 activity of Andrographis paniculata extract and its major component andrographolide in human lung epithelial cells and cytotoxicity evaluation in major organ cell representatives, J Nat Prod
Shu, He, Sun, Lin, Lu et al., Factors influencing viral clearance in mild COVID-19 and clinical characteristics of asymptomatic participants, Biomed Res Int, doi:10.1155/2021/5909612
Tanwettiyanont, Piriyachananusorn, Sangsoi, Boonsong, Sunpapoa et al., Use of Andrographis paniculata (Burm.f.) Wall. ex Nees and risk of pneumonia in hospitalised participants with mild coronavirus disease 2019: a retrospective cohort study, Front Med (Lausanne), doi:10.3389/fmed.2022.947373
Ucan, Cerci, Efe, Akgun, Ozmen et al., Benefits of treatment with favipiravir in hospitalized participants for COVID-19: a retrospective observational casecontrol study, Virol J, doi:10.1186/s12985-021-01577-1
Wanaratna, Leethong, Inchai, Chueawiang, Sriraksa et al., Efficacy and safety of Andrographis paniculata extract in participants with mild COVID-19: a randomized controlled trial, Arch Intern Med Res, doi:10.26502/aimr.0125
Zhang, Lv, Zhou, Xie, Xu et al., Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, openlabel and randomized controlled trial, Phytother Res, doi:10.1002/ptr.7141
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit